Spirulina (Phycocyanin).

Spirulina's cobalamin is largely pseudovitamin B12, which binds human B12 carrier proteins without serving as a cofactor. A genuine cobalamin source belongs in the formula rather than relying on the algae for B12.

Phycocyanin's open chain bilin chromophore quenches radicals and is itself oxidised in the process, and ascorbate is the water-phase reductant that returns oxidised species to their active state. Ascorbate also slows phycocyanin bleaching in the product.

Phycocyanin is a water-soluble protein pigment while astaxanthin spans the lipid bilayer with its polar ends anchored at both membrane faces. The two act in different compartments.

Phycocyanin scavenges radicals stoichiometrically, while selenium-dependent glutathione peroxidases remove peroxides catalytically and are not consumed. Pairing a scavenger with the enzyme system covers both halves of normal oxidant handling.

Cysteine availability is the rate-limiting input for glutathione synthesis, and glutathione is what regenerates most oxidised antioxidants in the cell. Supplying the substrate supports the system that recycles what phycocyanin cannot recycle on its own.

Whole spirulina supplies non-heme iron bound to phycobiliproteins, which is taken up through the ferrous transporter after reduction. Uptake therefore depends on the reducing conditions in the same meal rather than on the algal iron content alone.

Phycocyanin is a chromoprotein, not a small molecule. Pepsin and pancreatic proteases cut the apoprotein, and only then do chromophore-carrying peptides become available for uptake. Protease activity therefore sits upstream of anything phycocyanin does systemically. The step is well described biochemically and has not been quantified in a human co-supplementation trial.

Phycocyanin's radical-scavenging chemistry is aqueous, which leaves the lipid interior of membranes to tocopherol. Pairing the two covers both compartments rather than doubling up in one. The rationale is chemical partitioning; no trial in this candidate set measured the combination in people.

The two microalgae bring different pigment and nutrient profiles, chlorophyll and carotenoids from Chlorella against the phycobiliprotein of spirulina. Reviews describe overlapping activity across several pathways rather than one shared target. This is review-level synthesis, so read it as a common co-formulation practice with mechanistic plausibility rather than a measured additive effect.

Whole spirulina delivers a water-soluble phycobiliprotein and lipid-soluble carotenoids in the same matrix, which is why isolated phycocyanin and whole powder are not interchangeable ingredients. Formulators pairing purified phycocyanin with a carotenoid are rebuilding part of that natural profile. The pairing is compositional logic, not a trial result.

Phycocyanin scavenges radicals directly, while zinc supports normal function of an enzyme that does the same job catalytically. The two contributions are mechanistically distinct and could plausibly be complementary. This has not been tested as a pairing, and superoxide dismutase activity is a marker rather than a health outcome.

Both operate in the water phase of the cell and both are commonly reported in the same antioxidant marker panels. Whether one spares the other in people has not been measured. Marker movement in these panels is not itself an outcome.

The two cannot substitute for each other because they cannot reach the same places. A formulation carrying both covers membrane and cytosolic chemistry. No combination data exists in this candidate set.

Quercetin donates hydrogen atoms from its catechol ring; phycocyanin's activity runs through its open-chain tetrapyrrole and its protein scaffold. The chemistry is complementary rather than redundant. This is a mechanistic pairing with no human combination evidence here.

Spirulina protein is relatively low in methionine and cysteine, which dairy protein supplies well. Blending the two gives a more even amino acid pattern than either alone. This is protein-quality arithmetic, a compositional point rather than a clinical finding.

Both ingredients are studied for movement in the same circulating inflammatory markers, curcumin from the lipid phase and phycocyanin from the aqueous phase. The convergence is at the level of measured markers, and a marker is not a clinical outcome. No trial in this set combined them.

Lipoic acid crosses between compartments that phycocyanin cannot enter, so the two together span more of the redox network than either does alone. The reasoning is chemical. Nothing in this candidate set tested the pair.